מוגש מטעם רוש פרמצבטיקה (ישראל) בע"מ
References:
1. Clinical Gastroenterology and Hepatology 2006 41378-1384DOI: (10.1016/j.cgh.2006.08.011)
2. AASLD practice guidelines: prevention & management of gastroesophageal varices. Hepatology 2007: 46: 922-938.
3. Breder, V. V. et. Al. , IMbrave150: Exploratory Efficacy and Safety Results of Hepatocellular Carcinoma (HCC) Patients with Main Trunk and/or Contralateral Portal Vein Invasion (Vp4) Treated with Atezolizumab + Bevacizumab vs Sorafenib in a Global Phase III Study ASCO Annual Meeting. June 4–8, 2021. Abstract #4073
4. Cheng A. L. et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus Bevacizumab vs. Sorafenib for unresectable hepatocellular carcinoma. ASCO-GI 2021 and J Hepatol 2022; 76 (4): 862- 873
5. Boregowda U, Umapathy C, Halim N, Desai M, Nanjappa A, Arekapudi S, Theethira T, Wong H, Roytman M, Saligram S. Update on the management of gastrointestinal varices. World J Gastrointest Pharmacol Ther. 2019 Jan 21;10(1):1-21. doi: 10.4292/wjgpt.v10.i1.1. PMID: 30697445; PMCID: PMC6347650.